-
市場
-
產品
-
資訊
-
Moo社區
-
課堂
-
查看更多
-
功能介紹
-
費用費用透明,無最低余額限制
投資選擇、功能介紹、費用相關信息由Moomoo Financial Inc.提供
- English
- 中文繁體
- 中文简体
- 深色
- 淺色
Phoenix Biotech Acquisition Corp. (NASDAQ:PBAX) Short Interest Down 71.6% in October
Phoenix Biotech Acquisition Corp. (NASDAQ:PBAX) Short Interest Down 71.6% in October
Phoenix Biotech Acquisition Corp. (NASDAQ:PBAX – Get Rating) was the recipient of a large decline in short interest in the month of October. As of October 15th, there was short interest totalling 2,700 shares, a decline of 71.6% from the September 30th total of 9,500 shares. Based on an average daily trading volume, of 49,400 shares, the short-interest ratio is presently 0.1 days. Approximately 0.0% of the company's shares are sold short.
Phoenix Biotech Acquisition Stock Performance
PBAX stock remained flat at $10.17 during mid-day trading on Wednesday. 14 shares of the company's stock were exchanged, compared to its average volume of 41,075. Phoenix Biotech Acquisition has a 52 week low of $9.71 and a 52 week high of $11.76. The stock has a 50-day moving average of $10.10 and a two-hundred day moving average of $10.05.
Get Phoenix Biotech Acquisition alerts:Institutional Trading of Phoenix Biotech Acquisition
Several large investors have recently added to or reduced their stakes in the company. MMCAP International Inc. SPC increased its stake in Phoenix Biotech Acquisition by 200.0% in the 1st quarter. MMCAP International Inc. SPC now owns 750,000 shares of the company's stock valued at $7,504,000 after buying an additional 500,000 shares during the period. Saba Capital Management L.P. increased its stake in shares of Phoenix Biotech Acquisition by 14.7% in the first quarter. Saba Capital Management L.P. now owns 733,826 shares of the company's stock worth $7,342,000 after acquiring an additional 94,068 shares during the last quarter. Westchester Capital Management LLC acquired a new position in shares of Phoenix Biotech Acquisition in the second quarter worth $4,626,000. Wolverine Asset Management LLC raised its holdings in shares of Phoenix Biotech Acquisition by 161.7% during the second quarter. Wolverine Asset Management LLC now owns 404,576 shares of the company's stock worth $4,053,000 after acquiring an additional 250,010 shares in the last quarter. Finally, Context Capital Management LLC acquired a new stake in Phoenix Biotech Acquisition during the first quarter valued at $4,002,000. 62.98% of the stock is owned by institutional investors and hedge funds.
About Phoenix Biotech Acquisition
(Get Rating)Phoenix Biotech Acquisition Corp. does not have significant operations. The company intends to effect a merger, share exchange, asset acquisition, share purchase, reorganization, or similar business combination with one or more businesses. It engages in identifying and acquiring a business that focuses on the healthcare or healthcare related industries in the United States and Europe.
Featured Articles
- Get a free copy of the StockNews.com research report on Phoenix Biotech Acquisition (PBAX)
- Kimberly-Clark Products Post Weak Quarter Despite Raising Prices
- Why is Kraft Heinz Stock Moving Higher? It's a Great Bargain
- Is This The Bottom For Canopy Growth Corporation?
- Solar-Industry Small Cap Array Set For Big EPS Growth In 2023
- Unity Software is the Other Video Game Engine To Watch
Receive News & Ratings for Phoenix Biotech Acquisition Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Phoenix Biotech Acquisition and related companies with MarketBeat.com's FREE daily email newsletter.
Phoenix Biotech Acquisition Corp. (NASDAQ:PBAX – Get Rating) was the recipient of a large decline in short interest in the month of October. As of October 15th, there was short interest totalling 2,700 shares, a decline of 71.6% from the September 30th total of 9,500 shares. Based on an average daily trading volume, of 49,400 shares, the short-interest ratio is presently 0.1 days. Approximately 0.0% of the company's shares are sold short.
鳳凰生物科技收購公司(納斯達克代碼:PBAX-GET評級)是空頭股數10月份股價大幅下跌的接收方。截至10月15日,空頭股數共有2700股,比9月30日的9500股下降了71.6%。以日均成交量四萬九千四百股計算,目前短息比率為零點一天。該公司約0.0%的股票被賣空。
Phoenix Biotech Acquisition Stock Performance
鳳凰生物科技收購股票表現
PBAX stock remained flat at $10.17 during mid-day trading on Wednesday. 14 shares of the company's stock were exchanged, compared to its average volume of 41,075. Phoenix Biotech Acquisition has a 52 week low of $9.71 and a 52 week high of $11.76. The stock has a 50-day moving average of $10.10 and a two-hundred day moving average of $10.05.
週三午盤交易中,PBAX股價持平於10.17美元。該公司股票成交量為14股,而其平均成交量為41,075股。鳳凰生物科技收購的52周低點為9.71美元,52周高點為11.76美元。該股的50日移動均線切入位10.10美元,200日移動均線切入位10.05美元。
Institutional Trading of Phoenix Biotech Acquisition
鳳凰生物科技收購的機構交易
Several large investors have recently added to or reduced their stakes in the company. MMCAP International Inc. SPC increased its stake in Phoenix Biotech Acquisition by 200.0% in the 1st quarter. MMCAP International Inc. SPC now owns 750,000 shares of the company's stock valued at $7,504,000 after buying an additional 500,000 shares during the period. Saba Capital Management L.P. increased its stake in shares of Phoenix Biotech Acquisition by 14.7% in the first quarter. Saba Capital Management L.P. now owns 733,826 shares of the company's stock worth $7,342,000 after acquiring an additional 94,068 shares during the last quarter. Westchester Capital Management LLC acquired a new position in shares of Phoenix Biotech Acquisition in the second quarter worth $4,626,000. Wolverine Asset Management LLC raised its holdings in shares of Phoenix Biotech Acquisition by 161.7% during the second quarter. Wolverine Asset Management LLC now owns 404,576 shares of the company's stock worth $4,053,000 after acquiring an additional 250,010 shares in the last quarter. Finally, Context Capital Management LLC acquired a new stake in Phoenix Biotech Acquisition during the first quarter valued at $4,002,000. 62.98% of the stock is owned by institutional investors and hedge funds.
幾家大型投資者最近增持或減持了該公司的股份。MMPCAP國際公司在第一季度將收購的菲尼克斯生物科技公司的股份增加了200.0%。MmCap International Inc.SPC現在持有該公司75萬股股票,價值7504,000美元,在此期間又購買了50萬股。Saba Capital Management L.P.在第一季度增持了鳳凰生物科技收購股份14.7%。Saba Capital Management L.P.在上個季度增持了94,068股後,現在擁有733,826股該公司股票,價值7,342,000美元。Westchester Capital Management LLC在第二季度收購了菲尼克斯生物技術收購公司價值462.6萬美元的新股票頭寸。金剛狼資產管理有限責任公司在第二季度增持了菲尼克斯生物科技公司收購的股票161.7%。金剛狼資產管理有限責任公司在上個季度額外收購了250,010股後,現在擁有404,576股該公司股票,價值4,053,000美元。最後,Context Capital Management LLC在第一季度收購了菲尼克斯生物技術公司的新股份,價值4,002,000美元。62.98%的股票由機構投資者和對衝基金持有。
About Phoenix Biotech Acquisition
關於收購菲尼克斯生物科技公司
Phoenix Biotech Acquisition Corp. does not have significant operations. The company intends to effect a merger, share exchange, asset acquisition, share purchase, reorganization, or similar business combination with one or more businesses. It engages in identifying and acquiring a business that focuses on the healthcare or healthcare related industries in the United States and Europe.
菲尼克斯生物科技收購公司沒有重大業務。公司擬與一家或者多家企業實施合併、換股、資產收購、購股、重組或者類似的業務合併。它致力於識別和收購一家專注於美國和歐洲的醫療保健或醫療保健相關行業的企業。
Featured Articles
專題文章
- Get a free copy of the StockNews.com research report on Phoenix Biotech Acquisition (PBAX)
- Kimberly-Clark Products Post Weak Quarter Despite Raising Prices
- Why is Kraft Heinz Stock Moving Higher? It's a Great Bargain
- Is This The Bottom For Canopy Growth Corporation?
- Solar-Industry Small Cap Array Set For Big EPS Growth In 2023
- Unity Software is the Other Video Game Engine To Watch
- 免費獲取StockNews.com關於鳳凰生物科技收購的研究報告(PBAX)
- 金佰利產品儘管提價,但季度業績疲軟
- 為什麼卡夫亨氏的股票會走高?這是一筆很划算的交易
- 這是Canopy Growth公司的底部嗎?
- 2023年太陽能行業小型帽陣列將迎來每股收益的大幅增長
- Unity Software是另一個值得關注的視頻遊戲引擎
Receive News & Ratings for Phoenix Biotech Acquisition Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Phoenix Biotech Acquisition and related companies with MarketBeat.com's FREE daily email newsletter.
獲得《鳳凰生物科技收購日報》的新聞和評級-在下面輸入您的電子郵件地址,通過MarketBeat.com的免費每日電子郵件時事通訊接收對菲尼克斯生物技術收購和相關公司的最新新聞和分析師評級的每日簡要摘要。
moomoo是Moomoo Technologies Inc.公司提供的金融資訊和交易應用程式。
在美國,moomoo上的投資產品和服務由Moomoo Financial Inc.提供,一家受美國證券交易委員會(SEC)監管的持牌主體。 Moomoo Financial Inc.是金融業監管局(FINRA)和證券投資者保護公司(SIPC)的成員。
在新加坡,moomoo上的投資產品和服務是通過Moomoo Financial Singapore Pte. Ltd.提供,該公司受新加坡金融管理局(MAS)監管(牌照號碼︰CMS101000) ,持有資本市場服務牌照 (CMS) ,持有財務顧問豁免(Exempt Financial Adviser)資質。本內容未經新加坡金融管理局的審查。
在澳大利亞,moomoo上的金融產品和服務是通過Futu Securities (Australia) Ltd提供,該公司是受澳大利亞證券和投資委員會(ASIC)監管的澳大利亞金融服務許可機構(AFSL No. 224663)。請閱讀並理解我們的《金融服務指南》、《條款與條件》、《隱私政策》和其他披露文件,這些文件可在我們的網站 https://www.moomoo.com/au中獲取。
在加拿大,透過moomoo應用程式提供的僅限訂單執行的券商服務由Moomoo Financial Canada Inc.提供,並受加拿大投資監管機構(CIRO)監管。
在馬來西亞,moomoo上的投資產品和服務是透過Moomoo Securities Malaysia Sdn. Bhd. 提供,該公司受馬來西亞證券監督委員會(SC)監管(牌照號碼︰eCMSL/A0397/2024) ,持有資本市場服務牌照 (CMSL) 。本內容未經馬來西亞證券監督委員會的審查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd.,Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc和Moomoo Securities Malaysia Sdn. Bhd., 是關聯公司。
風險及免責聲明
moomoo是Moomoo Technologies Inc.公司提供的金融資訊和交易應用程式。
在美國,moomoo上的投資產品和服務由Moomoo Financial Inc.提供,一家受美國證券交易委員會(SEC)監管的持牌主體。 Moomoo Financial Inc.是金融業監管局(FINRA)和證券投資者保護公司(SIPC)的成員。
在新加坡,moomoo上的投資產品和服務是通過Moomoo Financial Singapore Pte. Ltd.提供,該公司受新加坡金融管理局(MAS)監管(牌照號碼︰CMS101000) ,持有資本市場服務牌照 (CMS) ,持有財務顧問豁免(Exempt Financial Adviser)資質。本內容未經新加坡金融管理局的審查。
在澳大利亞,moomoo上的金融產品和服務是通過Futu Securities (Australia) Ltd提供,該公司是受澳大利亞證券和投資委員會(ASIC)監管的澳大利亞金融服務許可機構(AFSL No. 224663)。請閱讀並理解我們的《金融服務指南》、《條款與條件》、《隱私政策》和其他披露文件,這些文件可在我們的網站 https://www.moomoo.com/au中獲取。
在加拿大,透過moomoo應用程式提供的僅限訂單執行的券商服務由Moomoo Financial Canada Inc.提供,並受加拿大投資監管機構(CIRO)監管。
在馬來西亞,moomoo上的投資產品和服務是透過Moomoo Securities Malaysia Sdn. Bhd. 提供,該公司受馬來西亞證券監督委員會(SC)監管(牌照號碼︰eCMSL/A0397/2024) ,持有資本市場服務牌照 (CMSL) 。本內容未經馬來西亞證券監督委員會的審查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd.,Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc和Moomoo Securities Malaysia Sdn. Bhd., 是關聯公司。
- 分享到weixin
- 分享到qq
- 分享到facebook
- 分享到twitter
- 分享到微博
- 粘贴板
使用瀏覽器的分享功能,分享給你的好友吧